Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-07-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a Supplemental Application for VIMPAT (lacosamide) filed by UCB, Inc.
-
FDA approval · 2015-07-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) filed by UCB, Inc.
-
FDA approval · 2015-06-25FDA Approved: BANZEL — Supplemental Application (Eisai Inc.)
The FDA approved a supplemental application for BANZEL (rufinamide) submitted by Eisai Inc.
-
FDA approval · 2015-06-23FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)
FDA approved the Original Application for Fludeoxyglucose F-18 (FDG F-18) radiopharmaceutical for PET imaging, establishing its labeling and…
-
FDA approval · 2015-06-23FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (The University of Utah DBA Cyclotron Radiochemistry Lab / Huntsman Cancer Institute)
FDA approved the original application for Fludeoxyglucose F-18 as a radiopharmaceutical imaging agent for PET scans, developed by the Univer…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-06-23Clinical Trial Update: Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia [Phase 4]
Phase 4 trial update evaluating levetiracetam as a convulsant therapy for elderly patients with dementia-related epilepsy; study completed w…
-
FDA approval · 2015-06-19FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved a supplemental application for FYCOMPA (perampanel) from Eisai Inc., resulting in an updated labeling for the drug.
-
FDA approval · 2015-06-19FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
FDA approved a supplemental application for Zonegran (zonisamide) from Advanz Pharma (US) Corp.
-
FDA approval · 2015-06-19FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for Lamotrigine Extended Release, adding an extended-release formulation to the approved lamotrigine…
-
FDA approval · 2015-06-13FDA Approved: ZONISAMIDE — Supplemental Application (Exelan Pharmaceuticals, Inc.)
FDA approved a supplemental application for Zonisamide submitted by Exelan Pharmaceuticals, Inc. under ANDA 077869.
-
FDA approval · 2015-06-13FDA Approved: ZONISAMIDE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for Zonisamide from BluePoint Laboratories, authorizing a generic version of zonisamide.
-
FDA approval · 2015-06-11FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
FDA has approved a Supplemental Application for APTIOM (eslicarbazepine acetate) from Sumitomo Pharma America, expanding labeling/indication…
-
FDA approval · 2015-06-10FDA Approved: EXTENDED PHENYTOIN SODIUM — Original Application (Aurobindo Pharma Limited)
FDA approved the Original Application (ANDA204309) for Extended Phenytoin Sodium from Aurobindo Pharma Limited, a generic extended-release f…
-
FDA approval · 2015-06-04FDA Approved: LEVETIRACETAM — Original Application (Major Pharmaceuticals)
FDA approved the Original Application for levetiracetam from Major Pharmaceuticals, making a generic version of the anticonvulsant available…
-
CLINICAL_TRIALS trial_result · 2015-06-03Clinical Trial Update: Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures [Phase 3]
Phase 3 trial results posted assessing long-term lacosamide as monotherapy and as adjunctive therapy for partial-onset seizures in epilepsy.
-
CLINICAL_TRIALS trial_result · 2015-05-29Clinical Trial Update: The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy [Phase 4]
Phase 4 trial comparing a low-dose lamotrigine and valproic acid combination against carbamazepine monotherapy in epilepsy, reporting on eff…
-
FDA approval · 2015-05-29FDA Approved: DIVALPROEX SODIUM — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal's generic divalproex sodium product through an Original Application (ANDA 203730).
-
CLINICAL_TRIALS trial_result · 2015-05-28Clinical Trial Update: STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy [Phase 2, Phase 3]
Clinical trial update for STIMEP evaluating subthalamic nucleus stimulation in patients with drug-resistant epilepsy; the Phase 2/3 study ha…
-
CLINICAL_TRIALS other · 2015-05-28Clinical Trial Update: Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures) [Phase 3]
Phase 3 TROCC trial evaluating quick oral treatment of cluster epileptic seizures was terminated.
-
FDA approval · 2015-05-21FDA Approved: LEVETIRACETAM — Original Application (Solco healthcare U.S., LLC)
FDA approves the original (generic) application for levetiracetam submitted by Solco Healthcare U.S., LLC.
-
FDA label_change · 2015-05-18FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal (lamotrigine) submitted by GlaxoSmithKline; the action updates the product labeling.
-
FDA approval · 2015-05-18FDA Approved: LEVETIRACETAM — Supplemental Application (Patrin Pharma, Inc.)
The FDA approved a supplemental application for levetiracetam from Patrin Pharma, Inc., indicating regulatory clearance related to an alread…
-
FDA approval · 2015-05-18FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Lamictal (lamotrigine) submitted by GlaxoSmithKline LLC. The action supplements the original…
-
FDA approval · 2015-05-18FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal ODT (lamotrigine) submitted by GlaxoSmithKline LLC. The approval concerns the supplemen…
-
CLINICAL_TRIALS trial_result · 2015-05-13Clinical Trial Update: A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures) [Phase 3]
Phase 3 double-blind, placebo-controlled trial evaluating Levetiracetam in epilepsy patients with generalized tonic-clonic seizures has comp…